Research to support the development of a pre-clinical asset.
A tech transfer company aimed to obtain insights into 2 cancer indications to guide the development of its partner’s preclinical asset, particularly understanding the current market landscape, unmet need, perception of cell immunotherapy and initial thoughts on the proposed TPPs.
Our Solution
GlobalData leveraged expertise in oncology to design PMR instruments and conduct tele-depth interviews with key opinion leaders (KOLs) within the target indications across US and EU3 (France, Germany, and UK).
Outcome
GlobalData analyzed and consolidated all findings from PMR, and delivered a summary presentation with a robust understanding
of disease management, unmet needs, and insights and recommendations on client’s TPPs.
Our consultants work closely with you to understand requirements and develop a tailored approach and deliverables.
